4 analysts have expressed a variety of opinions on TScan Therapeutics (NASDAQ:TCRX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Analysts’ evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.75, with a high estimate of $15.00 and a low estimate of $10.00. Consistency is reflected as the current average remains at the same level as the previou…